TheraRadar
← All Biomarkers

ER (Estrogen Receptor)

27 drugs

Predictive biomarker for patient selection in 16 indications

27
Approved Drugs
16
Indications
22
Companies

ER (Estrogen Receptor) is a precision-medicine biomarker linked to 27 FDA-approved targeted drugs from 22 companies, spanning 16 indications including Vasomotor Symptoms, Osteoporosis, Vulvar and Vaginal Atrophy. Explore the targeted therapies, indications, testing methods, and companies developing ER (Estrogen Receptor) drugs below.

Search ER (Estrogen Receptor) Clinical Trials

Search recruiting trials on ClinicalTrials.gov

Drugs Targeting ER (Estrogen Receptor)

Drug Company Therapeutic Area
ACTIVELLA AMNEAL Women's Health
ANGELIQ Bayer Women's Health
BIJUVA MAYNE PHARMA INC Women's Health
CLIMARA Bayer Women's Health
CLIMARA PRO Bayer Women's Health
CONJUGATED ESTROGENS NOVAST LABS LTD Oncology
DIVIGEL VERTICAL PHARMS Women's Health
ELESTRIN Viatris Women's Health
ESTRADIOL AND NORETHINDRONE ACETATE XIROMED Women's Health
ESTROGEL ASCEND THERAPS US Women's Health
EVAMIST PADAGIS US Women's Health
EVISTA Eli Lilly Oncology
FASLODEX AstraZeneca Oncology
FEMRING MILLICENT MFG PR Women's Health
FULVESTRANT CHIA TAI TIANQING Oncology
FYAVOLV Lupin Women's Health
IMVEXXY MAYNE PHARMA INC Women's Health
MENOSTAR Bayer Women's Health
MINIVELLE NOVEN Women's Health
MYFEMBREE SUMITOMO PHARMA AM Women's Health
OSPHENA DUCHESNAY Women's Health
PREMPHASE 14/14 Pfizer Oncology
PREMPRO Pfizer Women's Health
RALOXIFENE HYDROCHLORIDE CADILA PHARMS LTD Oncology
SOLTAMOX MAYNE PHARMA COMMRCL Oncology
TOREMIFENE CITRATE RISING Oncology
VIVELLE-DOT Novartis Women's Health

ER (Estrogen Receptor) Indications

Vasomotor Symptoms Osteoporosis Vulvar and Vaginal Atrophy Breast Cancer Postmenopausal Osteoporosis Hypoestrogenism Prostate Cancer Heavy Menstrual Bleeding Uterine Leiomyoma Endometriosis Dyspareunia Vaginal Dryness Metastatic Breast Cancer Ductal Carcinoma in Situ Hypogonadism Primary Ovarian Failure